image
Healthcare - Biotechnology - NASDAQ - US
$ 1.81
3.43 %
$ 18.9 M
Market Cap
-0.3
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CRIS stock under the worst case scenario is HIDDEN Compared to the current market price of 1.81 USD, Curis, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CRIS stock under the base case scenario is HIDDEN Compared to the current market price of 1.81 USD, Curis, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CRIS stock under the best case scenario is HIDDEN Compared to the current market price of 1.81 USD, Curis, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CRIS

image
$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
10.9 M REVENUE
8.83%
-44.5 M OPERATING INCOME
7.84%
-43.4 M NET INCOME
8.49%
-39.6 M OPERATING CASH FLOW
-2.94%
29.4 M INVESTING CASH FLOW
-22.08%
3.44 M FINANCING CASH FLOW
-54.66%
2.38 M REVENUE
-28.85%
-10.2 M OPERATING INCOME
-12.93%
-10.6 M NET INCOME
-10.38%
-7.25 M OPERATING CASH FLOW
21.68%
0 INVESTING CASH FLOW
100.00%
7.54 M FINANCING CASH FLOW
-14.65%
Balance Sheet Curis, Inc.
image
Current Assets 26.4 M
Cash & Short-Term Investments 20 M
Receivables 3.35 M
Other Current Assets 3.04 M
Non-Current Assets 14.9 M
Long-Term Investments 0
PP&E 3.39 M
Other Non-Current Assets 11.5 M
48.46 %8.12 %7.36 %8.22 %27.83 %Total Assets$41.3m
Current Liabilities 19 M
Accounts Payable 3.02 M
Short-Term Debt 2.67 M
Other Current Liabilities 13.3 M
Non-Current Liabilities 28.2 M
Long-Term Debt 3.24 M
Other Non-Current Liabilities 25 M
6.40 %5.65 %28.21 %6.85 %52.90 %Total Liabilities$47.3m
EFFICIENCY
Earnings Waterfall Curis, Inc.
image
Revenue 10.9 M
Cost Of Revenue 98 K
Gross Profit 10.8 M
Operating Expenses 55.4 M
Operating Income -44.5 M
Other Expenses -1.15 M
Net Income -43.4 M
20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)11m(98k)11m(55m)(45m)1m(43m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
99.10% GROSS MARGIN
99.10%
-408.34% OPERATING MARGIN
-408.34%
-397.77% NET MARGIN
-397.77%
723.39% ROE
723.39%
-105.15% ROA
-105.15%
-178.81% ROIC
-178.81%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Curis, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -43.4 M
Depreciation & Amortization 187 K
Capital Expenditures 0
Stock-Based Compensation 5.93 M
Change in Working Capital -3.72 M
Others 328 K
Free Cash Flow -39.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Curis, Inc.
image
CRIS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Curis, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement LEXINGTON, Mass. , July 2, 2025 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 1,538,460 shares ("Shares") of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. prnewswire.com - 1 week ago
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) LEXINGTON, Mass. , May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy to purchase 200,000 shares of Curis common stock, with a grant date of May 1, 2025 (the "Inducement Grant"). prnewswire.com - 2 months ago
Curis, Inc. (CRIS) Q1 2025 Earnings Call Transcript Curis, Inc. (NASDAQ:CRIS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Ahmed Hamdy - Chief Medical Officer Jonathan Zung - Chief Development Officer Conference Call Participants Li Watsek - Cantor Fitzgerald Kripa Devarakonda - Truist Securities Operator Good morning ladies and gentlemen and welcome to the Curis Provides First Quarter 2025 Business Update Conference Call. At this time, all lines are in listen-only mode. seekingalpha.com - 2 months ago
Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates Curis (CRIS) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $2.05 per share a year ago. zacks.com - 2 months ago
Curis Provides First Quarter 2025 Business Update Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass. prnewswire.com - 2 months ago
Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025 LEXINGTON, Mass. , April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. prnewswire.com - 2 months ago
Curis to Present at Upcoming Healthcare Conference in April LEXINGTON, Mass. , April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025 with a fireside chat and company presentation. prnewswire.com - 3 months ago
Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript Curis, Inc. (NASDAQ:CRIS ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Diantha Duvall - CFO Jim Dentzer - President and CEO Jonathan Zung - Chief Development Officer Conference Call Participants Sean McCutcheon - Raymond James Li Watsek - Cantor Fitzgerald Ed White - H.C. Wainwright Operator Good morning, and welcome to Curis's Fourth Quarter 2024 Business Update Call. seekingalpha.com - 3 months ago
Curis Provides Fourth Quarter 2024 Business Update FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU Orphan Drug Designation for PCNSL granted in both US and EU Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass. prnewswire.com - 3 months ago
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 LEXINGTON, Mass. , March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m. prnewswire.com - 3 months ago
Curis Announces Additional Data from TakeAim Leukemia Study LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting. prnewswire.com - 6 months ago
Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript Curis, Inc. (NASDAQ:CRIS ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Jonathan Zung - Chief Development Officer Conference Call Participants Ed White - H.C. Wainwright Billal Jahangiri - Truist Securities Daniel Bronder - Cantor Sean McCutcheon - Raymond James Operator Good morning, ladies and gentlemen, and welcome to the Curis Third Quarter 2024 Business Update Call. seekingalpha.com - 7 months ago
8. Profile Summary

Curis, Inc. CRIS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 18.9 M
Dividend Yield 0.00%
Description Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Contact Building C, Lexington, MA, 02421 https://www.curis.com
IPO Date Aug. 1, 2000
Employees 34
Officers Ms. Rachel Blasbalg Senior Director of Human Resources Dr. Ahmed M. Hamdy M.D. Chief Medical Officer Dr. Robert E. Martell M.D., Ph.D. Chief Scientific Officer Ms. Nancy Soohoo Vice President & General Counsel Mr. Mark W. Noel Vice President of Technology Management & Intellectual Property Ms. Diantha Duvall CPA, M.B.A. Chief Financial Officer and Principal Financial & Accounting Officer Dr. Jonathan B. Zung Ph.D. Chief Development Officer Mr. James E. Dentzer President, Chief Executive Officer, Secretary, Treasurer & Director